Valuation: Avicanna Inc.

Market Cap 14.46M 10.32M 9M 8.5M 7.72M 990M 14.52M 102M 39.29M 504M 38.78M 37.92M 1.62B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 14.18M 10.12M 8.83M 8.33M 7.57M 971M 14.24M 99.83M 38.53M 494M 38.02M 37.18M 1.59B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.71%
Yield 2024 *
-
Yield 2025 -
1 day-4.55%
1 week-4.55%
Current month-19.23%
1 month-16.00%
3 months-19.23%
6 months-34.38%
Current year-53.33%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.1
0.14
Current year 0.1
Extreme 0.095
0.24
1 year 0.1
Extreme 0.095
0.3
3 years 0.1
Extreme 0.095
0.6
5 years 0.1
Extreme 0.095
1
10 years 0.1
Extreme 0.095
7.4
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
10/09/26 Buy

Director

233,000 0.1734%
12/06/26 Sell

Director

333,000 0.2647%
27/05/26 Buy

Director

160,000 0.1272%
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%-4.55%-58.82%-77.42% 10.83M
+0.11%+2.71%+0.33%+28.59% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%+0.67%+11.79%+40.51% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+8.12%+22.15%+38.93% 15.32B
-3.14%+31.91%-10.60% - 14.5B
Average -1.35%+3.69%+39.06%+95.92% 26.55B
Weighted average by Cap. -1.03%+2.74%+65.68%+131.92%

Financials

2024 2025
Net sales 25.46M 18.17M 15.85M 14.96M 13.59M 1.74B 25.57M 179M 69.17M 887M 68.27M 66.76M 2.85B 25.48M 18.19M 15.86M 14.98M 13.6M 1.75B 25.59M 179M 69.22M 887M 68.32M 66.81M 2.85B
Net income -3.62M -2.58M -2.25M -2.13M -1.93M -248M -3.63M -25.47M -9.83M -126M -9.7M -9.49M -405M -2.76M -1.97M -1.72M -1.62M -1.47M -189M -2.77M -19.43M -7.5M -96.09M -7.4M -7.23M -309M
Net Debt -339K -242K -211K -199K -181K -23.21M -340K -2.39M -920K -11.8M -909K -888K -37.96M -281K -200K -175K -165K -150K -19.22M -282K -1.98M -762K -9.77M -753K -736K -31.45M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
18/09/26 CA$0.1050 -4.55% 91,000
17/09/26 CA$0.1100 0.00% 21,245
16/09/26 CA$0.1100 -8.33% 56,001
15/09/26 CA$0.1200 0.00% 12,500
14/09/26 CA$0.1200 +9.09% 17,504
  1. Stock Market
  2. Stocks
  3. AVCN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!